Biodel Inc. (BIOD) to Present New Preclinical Glucagon Data During Corporate Overview at JMP Securities Healthcare Conference
7/3/2013 8:07:41 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
DANBURY, Conn., July 3, 2013 (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD) announced today that management will present new preclinical pharmacokinetic and pharmacodynamic data on its glucagon formulation intended for use in a novel auto-reconstitution device. Biodel's glucagon injection system is designed to improve on existing treatments for severe hypoglycemia. These data will be presented during a corporate overview of the Company on Tuesday, July 9, 2013 at 12:30 p.m. EDT at the Eighth Annual JMP Securities Healthcare Conference in New York City.
Help employers find you! Check out all the jobs and post your resume.
comments powered by